China: Pharmaceutical Development Platform Wuxi to Build New R&D Center in Shanghai
STA Pharmaceutical, a subsidiary of Wuxi Apptec, has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.
Shanghai/China — The company has already established a process development platform with over 1,000 scientists and five sites located in China and the United States. The Jinshan site currently focuses on manufacturing innovative Active Pharmaceutical Ingredients (APIs) and advanced intermediates from kilo to metric ton scale. The site has been approved by multiple international regulatory agencies, including the FDA.
The new R&D center will be located next to the existing Jinshan drug substance manufacturing site, adding more than 30,000 m2 of laboratory space and 500 scientists. Upon completion, the expanded Jinshan campus will be able to offer an integrated one-site solution for partners to push forward APIs and advanced intermediates — from preclinical and clinical development through to global commercial launch. The new campus will also provide access to industry-leading technology platforms such as flow chemistry, biocatalysis, and high potency from laboratory to commercial scale.
Shanghai Jinshan District has enjoyed sustained economic growth in recent years, via its strategic focus on “smart manufacturing”, and has attracted many biotechnology and pharmaceutical companies including Wuxi STA.